BBLG — Bone Biologics Income Statement
0.000.00%
Last trade - 00:00
- $1.42m
- -$1.61m
2019 December 31st | 2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 2.45 | 0.825 | 1.1 | 3.67 | 9.84 |
Operating Profit | -2.45 | -0.825 | -1.1 | -3.67 | -9.84 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.42 | -1.82 | -1.61 | -1.48 | -8.95 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.42 | -1.82 | -1.61 | -1.48 | -8.95 |
Net Income Before Extraordinary Items | |||||
Net Income | -3.42 | -1.82 | -1.61 | -1.48 | -8.95 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.42 | -1.82 | -1.61 | -1.48 | -8.95 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -282 | -150 | -85.1 | -31.2 | -32.4 |